Background: Mutations in the bone morphogenetic protein type 2 receptor (BMPR2) are responsible for the majority of cases of heritable pulmonary arterial hypertension (PAH). Low penetrance of BMPR2 mutation in heritable PAH, however, suggests the involvement of second-hit elements in the pathogenesis of PAH. We have previously reported that treatment with endothelin-1 induced in vitro increased expression of noggin, an intrinsic bone morphogenetic protein antagonist, in human pulmonary artery smooth muscle cells (PA-SMCs). Moreover, chronic exposure to hypoxia is a well-known inducer of remodeling in pulmonary arteries. However, the potential link between chronic hypoxia exposure and noggin expression has not been elucidated. Aims: We hypothesized that hypoxia could induce, in PA-SMCs, the expression of endothelin-1 which could secondarily result in the upregulation of noggin. Methods and results: Cultured human PA-SMCs were treated for 3, 6, 24, and 48 h with the hypoxiamimetic agent, cobalt chloride (CoCl 2 ; 100 μM) and gene expressions of preproendothelin-1 (ppET1), endothelin converting enzyme-1 (ECE1) and noggin were then evaluated by QRT-PCR. CoCl 2 treatment progressively increased the expressions of ppET1 and noggin, with maximal response after 24 h and 48 h of stimulation respectively. Gene expression of ECE1 was not changed. After pretreatment or not with a non-selective endothelin receptor antagonist (bosentan), we stimulated PA-SMCs with CoCl 2 for 5 h. Gene expression of noggin significantly increased after CoCl 2 treatment and this reaction was not changed by pretreatment with bosentan. Conclusions: Noggin, an intrinsic bone morphogenetic protein antagonist, was upregulated by CoCl 2 , independent of hypoxia-induced endothelin-1 pathway at earlier timing (5 h Background: Increased arterial stiffness is an independent risk factor for cardiovascular disease. The −401 T/C and insertion/deletion (I/D) polymorphisms of estrogen receptor-alpha and angiotensin-converting enzyme (ACE) genes are associated with arterial stiffness. We examined the effect of this combination of single-nucleotide polymorphisms on the risk for increased arterial stiffness. Methods: Our cross-sectional study comprised 403 middle-aged and older human participants. We determined the genotypes of −401 T/C and I/D single-nucleotide
Background: Mutations in the bone morphogenetic protein type 2 receptor (BMPR2) are responsible for the majority of cases of heritable pulmonary arterial hypertension (PAH). Low penetrance of BMPR2 mutation in heritable PAH, however, suggests the involvement of second-hit elements in the pathogenesis of PAH. We have previously reported that treatment with endothelin-1 induced in vitro increased expression of noggin, an intrinsic bone morphogenetic protein antagonist, in human pulmonary artery smooth muscle cells (PA-SMCs). Moreover, chronic exposure to hypoxia is a well-known inducer of remodeling in pulmonary arteries. However, the potential link between chronic hypoxia exposure and noggin expression has not been elucidated. Aims: We hypothesized that hypoxia could induce, in PA-SMCs, the expression of endothelin-1 which could secondarily result in the upregulation of noggin. Methods and results: Cultured human PA-SMCs were treated for 3, 6, 24, and 48 h with the hypoxiamimetic agent, cobalt chloride (CoCl 2 ; 100 μM) and gene expressions of preproendothelin-1 (ppET1), endothelin converting enzyme-1 (ECE1) and noggin were then evaluated by QRT-PCR. CoCl 2 treatment progressively increased the expressions of ppET1 and noggin, with maximal response after 24 h and 48 h of stimulation respectively. Gene expression of ECE1 was not changed. After pretreatment or not with a non-selective endothelin receptor antagonist (bosentan), we stimulated PA-SMCs with CoCl 2 for 5 h. Gene expression of noggin significantly increased after CoCl 2 treatment and this reaction was not changed by pretreatment with bosentan. Conclusions: Noggin, an intrinsic bone morphogenetic protein antagonist, was upregulated by CoCl 2 , independent of hypoxia-induced endothelin-1 pathway at earlier timing (5 h). Background: Increased arterial stiffness is an independent risk factor for cardiovascular disease. The −401 T/C and insertion/deletion (I/D) polymorphisms of estrogen receptor-alpha and angiotensin-converting enzyme (ACE) genes are associated with arterial stiffness. We examined the effect of this combination of single-nucleotide polymorphisms on the risk for increased arterial stiffness. Methods: Our cross-sectional study comprised 403 middle-aged and older human participants. We determined the genotypes of −401 T/C and I/D single-nucleotide polymorphisms in estrogen receptor-alpha and ACE by TaqMan PCR method. We also measured arterial stiffness by brachial-ankle pulsewave velocity (baPWV). Subjects were divided into high arterial stiffness and low arterial stiffness groups, with the dividing line set at the median value of baPWV. Results: The odds ratio for the presence of high arterial stiffness in individuals having the TT genotype of estrogen receptor-alpha compared with those having the other genotypes (TC and CC) was 2.46. With regard to the I/D polymorphism in ACE, the odds ratio for the presence of high arterial stiffness in individuals having the II genotype of ACE when compared with those having the other genotypes (ID and DD) was 1.99. Interestingly, the odds ratio was 5.31 for individuals having a combination of the TT genotype of estrogen receptor-alpha and II genotype of ACE when compared with those having a combination of TC and CC genotypes of estrogen receptoralpha and ID and DD genotypes of ACE. Conclusion: We revealed that a combination of the TT and II polymorphisms in estrogen receptor-alpha and ACE remarkably increased the risk for elevation of arterial stiffness in middle-aged and older humans. In contrast, left ventricular (LV) function has been focused as a novel determinant of prognosis in patients with c-ToF. We aimed to assess RV and LV volume in consideration of interaction with biventricular EF. Methods: We studied 45 patients with repaired ToF (23 males, 20.8 yrs, range 7-49 yrs). We examined 2-dimensional and 3-dimensinoal transthoracic echocardiography. To determine the severity of pulmonary stenosis (PS), we recorded the maximum flow velocity through the pulmonary valve obtained from continuous wave Doppler measurement by 2-dimensional echocardiography. The pressure gradients were calculated from this velocity using a simplified Bernoulli's equation. RV and LV end diastolic volume index (EDVI, ml/m 2 ), end systolic volume index (ml/m 2 ), stroke volume index (ml/m 2 ) and ejection fractions (EF) were measured with 3-dimensional transthoracic echocardiographic system (RV; Tomtec imaging systems, LV; 4D auto LVQ. GE Vivid E9, Japan). Results: RVEDVi and LVEDVi measured were 80.2 ± 22.6 ml/m 2 and 53.0 ± 10.1 ml/m 2 , respectively. RV/LV EDVI ratio (1.57 ± 0.59) was negatively correlated with RVEF (r = −0.350, p = 0.021). In the multivariate stepwise analysis, LVEF was associated with RV/LV EDVI ratio and RVEF (R = 0.518). On the other hand, the degree of PS didn't correlate with biventricular volume and function. Conclusions: LVEF may be affected rather by RV/LV volume ratio and RVEF in the patients with c-ToF. doi:10.1016/j.lfs.2013.12.097
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